DEDzhannet Anuarovna Elmurzaeva

Dzhannet Anuarovna Elmurzaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dzhannet Anuarovna Elmurzaeva has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Matrix metalloproteinase 2 as a biological marker in heart failure

    by A.M. Alieva, I.E. Baykova, N.KH. Khadzhieva, A.B. Sultangalieva, D.A. Elmurzaeva, A.M. Rakhaev, I.G. Nikitin

    Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.


  • Open Access

    Asprosin as a novel biological marker of atherosclerosis and carbohydrate metabolism disorders

    by Amina M. Alieva, Irina E. Baykova, Nyurzhanna Kh. Khadzhieva, Albina B. Sultangalieva, Alik M. Rakhaev, Dzhannet A. Elmurzaeva, Alim O. Asanov, Irina V. Kovtyukh, Elina Z. Etezova, Igor G. Nikitin, et al.

    Cardiovascular diseases represent a major global medical, social, and economic challenge. Active research is being conducted to identify new biological markers and therapeutic targets to develop effective approaches for risk stratification and secondary prevention of cardiovascular diseases. Despite the identification of numerous cardiovascular biomarkers, their translation into clinical practice has largely been unsuccessful. Recently, researchers have increasingly focused on asprosin. The primary objective of this article is to analyze existing studies on the role of asprosin as a biomarker in atherosclerosis and carbohydrate metabolism disorders. An increasing body of experimental evidence indicates that this biomarker contributes to the development and progression of atherosclerosis, diabetes mellitus, obesity, and polycystic ovary syndrome. Asprosin regulates various physiological processes, including appetite stimulation, glucose release, insulin secretion, apoptosis, and inflammation. Based on available clinical data, asprosin appears to be a promising molecule with both diagnostic and prognostic value in the context of atherosclerosis and carbohydrate metabolism disorders. Further research is needed to explore asprosin as an additional laboratory biomarker. Modulation of asprosin concentration and expression may become a promising therapeutic strategy for patients with atherosclerosis and carbohydrate metabolism disorders.

  • The role of matrix metalloproteinase 9 as a biological marker in heart failure

    by Amina M. Alieva, Alik M. Rakhaev, Albina B. Sultangalieva, Irina E. Baykova, Aila M. Karakizova, Gayane G. Totolyan, Jannet A. Elmurzaeva, Makhty I. Akkiev, Linda A. Khachukaeva, Alim O. Asanov, et al.

    Heart failure (HF) is an important medical, social and economic problem. The study of new biological markers deepens our understanding of the pathogenesis of this disease. In modern cardiology, there is a growing interest in matrix metalloproteinases (MMPs). These enzymes play an important role in tissue remodeling, angiogenesis, as well as in cell proliferation, migration and differentiation. The purpose of this literature review is to analyze current experimental and clinical data on MMP-9 as a new diagnostic and prognostic marker in HF. This review presents an analysis of modern publications on a given topic. We conducted an analysis of literature sources covering all important materials as of 01.12.2024. Experimental studies have established that MMP-9 is a key participant in cardiac remodeling, since it is directly involved in the degradation of extracellular matrix proteins and the activation of profibrotic pathways, as well as cytokines and chemokines. Clinical trial data indicate the significant importance of MMP-9 for diagnosis and prognosis in patients with HF.

  • Diagnostic, prognostic and therapeutic aspects of apelin in cardiovascular diseases

    by Amina M. Alieva, Natalia V. Teplova, Elena V. Reznik, Irina E. Baykova, Nyurzhanna Kh. Khadzhieva, Bela Z. Balagova, Alik M. Rakhaev, Dzhannet A. Elmurzaeva, Makhty I. Akkiev, Madina Ya. Shavaeva, et al.

    Biological markers have been thoroughly incorporated into clinical practice as a convenient and simple method for diagnosing and monitoring the condition of patients. The analysis of biomarkers has found its niche in oncology; however, their application in cardiovascular diseases is still in its infancy. Studies on apelin indicate the potential diagnostic and prognostic significance of the assessment of this marker in patients with cardiovascular diseases. The beneficial effect of apelin on the heart and blood vessels allows us to consider this marker as a therapeutic target. The combination of apelin with other biological markers, particularly brain natriuretic peptide and its precursor, may increase the predictive value of apelin.


  • Open Access

    The role of interleukin-27 in atherosclerotic cardiovascular diseases: A review

    by Amina M. Alieva, Natalia V. Teplova, Elena V. Reznik, Leyla R. Sarakaeva, Alik M. Rahaev, Dzhannet A. Elmurzaeva, Makhty I. Akkiev, Madina Ya. Shavaeva, Maryana A. Akkieva, Igor G. Nikitin

    The main cause of many cardiovascular diseases is atherosclerosis. The atherosclerotic process, manifested by acute vascular accidents, such as myocardial and/or cerebral infarction, or chronic ischemic conditions, such as coronary heart disease and cerebrovascular disease, is essentially a systemic inflammatory process. The significant role of T-cells, macrophages, neutrophils and cytokines in this pathological process has been proven. The presented literature review indicates the potentially important diagnostic and prognostic value of the interleukin-27 assessment. It is expected that further scientific and clinical studies will demonstrate the possibility of using this cytokine as an additional laboratory tool for the diagnosis, risk stratification and prediction of cardiovascular events in patients with a cardiac profile.

  • Interleukin-13 and cardiovascular diseases: literature review

    by Amina Magomedovna Alieva, Elena Vladimirovna Reznik, Natalia Vadimovna Teplova, Leyla Ramazanovna Sarakaeva, Elena Valerievna Surskaya, Dzhannet Anuarovna Elmurzaeva, Madina Yakubovna Shavaeva, Alik Magomedovich Rakhaev, Irina Aleksandrovna Kotikova, Igor Gennadievich Nikitin

    Cardiovascular diseases remain the leading cause of death worldwide despite significant advances in medicine and increased life expectancy. It is very important to search for and study new cardiovascular biological markers that can help the early diagnosis of cardiovascular diseases, serve as a laboratory tool for assessing the effectiveness of treatment, be a predictive marker of possible adverse clinical outcomes, and be a significant criterion for risk stratification. This review aims to consider interleukin-13 (IL-13) as a diagnostic and prognostic biomarker in cardiovascular pathology. IL-13 is involved in the development of many cardiovascular diseases, according to variousin vitroandin vivostudies, but its role remains unclear until the end. IL-13 has a positive effect, promoting the development of the heart at an early stage and facilitating the recovery of the heart after a myocardial infarction. Due to the induction of fibrosis and adverse cardiac remodeling, long-term IL-13 synthesis appears to be a risk factor for adverse outcomes in chronic cardiovascular diseases, such as heart failure. Understanding the effect of IL-13 on cardiac metabolism will shed light on possible new pathogenetic mechanisms for the development of heart disease. As a rule, an increase in the level of IL-13 in the blood serum goes in parallel with its expression in the tissues of the heart. However, the dissociation of systemic inflammatory reactions and local expression is not excluded. The introduction of IL-13 can restore the regenerative capacity of cardiomyocytes and reduce cardiac dysfunction. IL-13 deficiency limits the proliferation of cardiomyocytes, induces compensatory hypertrophy of cardiomyocytesin vitroand deletion of IL-13, leads to cardiac dysplasia, and impairs recovery processesin vivo. Although IL-13 is associated with cardiac fibrosis, cardiomyocyte proliferation, myocardial hypertrophy, immune cell recruitment and differentiation, and chemokine secretion in the heart, it is precise signaling pathways and underlying mechanisms of action remain poorly understood.


  • Biomarkers in cardiology: microRNA and heart failure

    by Alieva A.M. Alieva, Teplova N.V. Teplova, Kislyakov V.A. Kislyakov, Voronkova K.V. Voronkova K, Shnakhova L.M. Shnakhova, Valiev R.K. Valiev, Rakhaev A.M. Rakhaev, Elmurzaeva D.A. Elmurzaeva, Malkarova D.S. Malkarova, Nikitin I.G. Nikitin, et al.


  • Open Access

    Gamma-glutamyl transpeptidase is a promising biological marker of heart failure

    by A. M. Alieva, I. E. Baykova, K. V. Voronkova, N. V. Teplova, L. M. Shnakhova, R. K. Valiev, Д. А. Эльмурзаева, A. M. Rakhaev, M. R. Kalova, I. G. Nikitin

    Introduction. Currently, the search and study of new biological markers that can help early diagnosis of heart failure, serve as a laboratory tool for assessing the effectiveness of therapy, be a predictive marker of possible adverse clinical outcomes and a significant criterion for risk stratification is very relevant. While cardiospecific markers, including natriuretic peptides, their precursors, and highly sensitive troponins, are widely used in clinical practice, the need to use other markers does not have sufficient evidence. aspect of a biological marker of heart failure.Gamma-glutamyl transpeptidase is an enzyme localized on the outer side of cell membranes and involved in the metabolism of glutathione and cysteine. This enzyme is a dimeric glycoprotein (68 kDa), consisting of 2 subunits – a large and a small (46 and 22 kDa). Gamma-glutamyl transpeptidase is encoded by a multigene family consisting of at least 7 different genes located on chromosome 22; however, only 1 of these genes is involved in the formation of a functional enzyme. Gamma-glutamyl transpeptidase was found in all cells except erythrocytes. There is a significant variability in enzyme activity, which is especially high in tissues with a secretory and absorptive function, such as the kidneys, biliary tract, intestines, and epididymis.Purpose of the review is to present an overview of current publications devoted to the study of γ-glutamyl transpeptidase in the aspect of a biological marker of heart failure.Materials and methods. The analysis of literature sources (foreign and domestic articles) was carried out in the databases: PubMed, RSCI, MedLine, Google Scholar, Science Direct. The search was performed according to the following keywords: biological markers, heart failure, γ-glutamyl transpeptidase, biological markers, heart failure, γ-glutamyl transpeptidase.Results. In addition to its clinical use as a test for liver disease, biliary tract disease, and alcohol abuse, γ-glutamyl transpeptidase is of great interest because of its association with cardiovascular disease, diabetes, metabolic syndrome, and cancer. In the literature available to us, we found a small number of works devoted to the study of γ-glutamyl transpeptidase in patients with heart failure. In the review, we have presented data from experimental and clinical studies indicating a clear link between γ-glutamyl transpeptidase and heart failure. The pathogenetic mechanism of the possible relationship between γ-glutamyl transpeptidase and heart failure is not completely clear. The localization of this enzyme in tissues with a transport function has led to the assumption that it is involved in the transport of amino acids through the γ-glutamyl cycle.Conclusion. Further deeper understanding of the structure and function of the enzyme is needed, as well as future clinical studies to determine the diagnostic, prognostic and possibly therapeutic significance of this biological marker.


  • Resistin and cardiovascular pathology

    by Alieva A.M. Alieva, Baykova I.E. Baykova, Khadzhieva N.H. Khadzhieva, Ettinger O.A. Ettinger, Arakelyan R.а. Arakelyan, Valiev R.K. Valiev, Rakhaev A.M. Rakhaev, Batov М.а. Batov, Elmurzaeva D.а. Elmurzaeva, Malkarova D.S. Malkarova, et al.


  • Poliomyositis in a 58-year-old man

    by Alieva A.M. Alieva, Voronkova K.V. Voronkova, Shnakhova L.M. Shnakhova, Almazova I.I. Almazova, Tikhomirova A.S. Tikhomirova, Brutskaya L.A. Brutskaya, Surkhanova A.A. Surkhanova, Volynkina V.M. Volynkina, Kudaeva M.V. Kudaeva, Pokrovskaya A.V. Pokrovskaya, et al.